Quantitative Gradient Echo MRI Identifies Dark Matter as a New Imaging Biomarker of Neurodegeneration that Precedes Tisssue Atrophy in Early Alzheimer's Disease

Alzheimer's disease: from early pathogenesis to novel therapeutic approaches

The mainstay behind Alzheimer's disease (AD) remains unknown due to the elusive pathophysiology of the disease. Beta-amyloid and phosphorylated Tau is still widely incorporated in various research studies while studying AD. However, they are not sufficient. Therefore, many scientists and researchers have dug into AD studies to deliver many innovations in this field. Many novel biomarkers, such as phosphoglycerate-dehydrogenase, clusterin, microRNA, and a new peptide ratio (Aβ37/Aβ42) in cerebral-spinal fluid, plasma glial-fibrillary-acidic-protein, and lipid peroxidation biomarkers, are mushrooming. They are helping scientists find breakthroughs and substantiating their research on the early detection of AD. Neurovascular unit dysfunction in AD is a significant discovery that can help us understand the relationship between neuronal activity and cerebral blood flow. These new biomarkers are promising and can take these AD studies to another level. There have also been big steps forward in diagnosing and finding AD. One example is self-administered-gerocognitive-examination, which is less expensive and better at finding AD early on than mini-mental-state-examination. Quantum brain sensors and electrochemical biosensors are innovations in the detection field that must be explored and incorporated into the studies. Finally, novel innovations in AD studies like nanotheranostics are the future of AD treatment, which can not only diagnose and detect AD but also offer treatment. Non-pharmacological strategies to treat AD have also yielded interesting results. Our literature review spans from 1957 to 2022, capturing research and trends in the field over six decades. This review article is an update not only on the recent advances in the search for credible biomarkers but also on the newer detection techniques and therapeutic approaches targeting AD.

Learning-based motion artifact removal networks for quantitative R 2 ∗ mapping

PURPOSE

To introduce two novel learning-based motion artifact removal networks (LEARN) for the estimation of quantitative motion- and B 0 -inhomogeneity-corrected R 2 ∗ maps from motion-corrupted multi-Gradient-Recalled Echo (mGRE) MRI data.

METHODS

We train two convolutional neural networks (CNNs) to correct motion artifacts for high-quality estimation of quantitative B 0 -inhomogeneity-corrected R 2 ∗ maps from mGRE sequences. The first CNN, LEARN-IMG, performs motion correction on complex mGRE images, to enable the subsequent computation of high-quality motion-free quantitative R 2 ∗ (and any other mGRE-enabled) maps using the standard voxel-wise analysis or machine learning-based analysis. The second CNN, LEARN-BIO, is trained to directly generate motion- and B 0 -inhomogeneity-corrected quantitative R 2 ∗ maps from motion-corrupted magnitude-only mGRE images by taking advantage of the biophysical model describing the mGRE signal decay.

RESULTS

We show that both CNNs trained on synthetic MR images are capable of suppressing motion artifacts while preserving details in the predicted quantitative R 2 ∗ maps. Significant reduction of motion artifacts on experimental in vivo motion-corrupted data has also been achieved by using our trained models.

CONCLUSION

Both LEARN-IMG and LEARN-BIO can enable the computation of high-quality motion- and B 0 -inhomogeneity-corrected R 2 ∗ maps. LEARN-IMG performs motion correction on mGRE images and relies on the subsequent analysis for the estimation of R 2 ∗ maps, while LEARN-BIO directly performs motion- and B 0 -inhomogeneity-corrected R 2 ∗ estimation. Both LEARN-IMG and LEARN-BIO jointly process all the available gradient echoes, which enables them to exploit spatial patterns available in the data. The high computational speed of LEARN-BIO is an advantage that can lead to a broader clinical application.